Connect with us

Business

CytoDyn Inc (OTCMKTS: CYDY) Announces Study to Investigate Leronlimab for Triple-negative Breast Cancer Treatment

Published

on

CytoDyn Inc (OTCMKTS: CYDY) has announced that there will be a study on the drug leronlimab and its efficacy in the treatment of triple-negative breast cancer (TNBC) on a humanized TNBC xenograft model. The assistant professor of Breast Medical Oncology Research at the University of Texas MD Anderson Cancer Centre, Jangsoon Lee, Ph.D, will lead the study. The study will investigate a potential synergistic effect on leronlimab and immune checkpoint blockade (ICB).

According to the CEO and President of CytoDyn, Nader Pourhassan, Ph.D., the study will look into the leronlimab’s immunomodulatory effects in the tumor microenvironment. The company is hopeful that the drug will offer an alternative therapy for people with breast cancer. CytoDyn thanks Dr. Scott Kelly, who arranged the research.

The U.S Food and Drug Administration (FDA) granted CytoDyn a Fast Track designation for leronlimab. This designation will enable the company to investigate the drug’s potential use in treating metastatic cancer and Human Immunodeficiency Virus (HIV).

Leronlimab works by binding to CCR5 receptors

Leronlimab could be used with HAART to treat people with HIV and treat metastatic triple-negative breast cancer (mTNBC). The drug works by binding to the CCR5 cellular receptor. Binding to these receptors in HIV patients could block the R5 strain of HIV from entering T-cells, thus protecting healthy T-cells from infection. Leronlimab does not work with other strains of HIV. However, R5 is the most dominant type of HIV. It might also be effective in the treatment of non-alcoholic steatohepatitis (NASH).

Previous research done on cancer shows that CCR5 receptors are responsibly for angiogenesis, tumor metastases and invasion. Blocking the receptors in animals has been shown to significantly reduce metastasis of breast and prostate cancer in animal models. Leronlimab, on the other hand, has been shown to reduce metastasis of breast cancer in xenograft models by over 97%.

CytoDyn is holding two clinical trials for leronlimab

Because of the results from these studies, the company is now holding two clinical trials. The first trial is Phase II in mTNBC, which the FDA a Fast Track Designation in 2019. The second is also a Phase II trial investigating the drug’s effect on 22 various solid cancer tumours.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

FEATURED STORIES

Business6 hours ago

CV Sciences Inc. (OTCMKTS: CVSI) Reports 8% Drop In Sales In Q3 2021 Attributable To Regulatory Uncertainty in CBD

Post Views: 7 CV Sciences Inc. (OTCMKTS: CVSI) has announced its third-quarter 2021 financial results for the period ending September...

INDUSTRIAL HEMP6 hours ago

AuxlyCannabis Group Inc. (OTCMKTS: CBWTF) Reports Net Revenue Growth 95% In Q3 2021

Post Views: 52 Auxly Cannabis Group Inc. (OTCMKTS: CBWTF) has announced its financial results for the third quarter and nine...

INDUSTRIAL HEMP7 hours ago

Vivo Cannabis Inc. (OTCMKTS: VVCIF) Releases Q3 2021 Net Revenue of $6.2 Million as It Expands Internationally

Post Views: 33 Vivo Cannabis Inc. (OTCMKTS: VVCIF) has released its Q3 2021 operating and financial results for the quarter...

Business7 hours ago

Rubicon Organics Inc. (OTCMKTS: ROMJF) Announces 124% YoY Growth In Revenue in Q3 2021 After Launching New Brands

Post Views: 11 Rubicon Organics Inc. (OTCMKTS: ROMJF) has released its Q3 2021 results ending September 30, 2021, in which...

Business1 day ago

Sugarbud Craft Growers Corp (OTCMKTS: SBUDF) Reports 120% Sequential Revenue Growth in Q3 2021

Post Views: 14 Sugarbud Craft Growers Corp (OTCMKTS: SBUDF) has filed its unaudited consolidated preliminary financial statements for the quarter...

Business1 day ago

Indiva Limited (OTCMKTS: NDAF) Reports 143% YoY increase in Revenue In Q3 2021

Post Views: 46 Indiva Limited (OTCMKTS: NDAF) has announced its operating and financial results for the third quarter ending September...